equityflowunderstand the flow and follow it

EquityFlow › Companies › Purespring

Purespring

Biotech · London, GB

Developer of gene therapies targeting kidney disease.

Founders

Moin Saleem (United Kingdom · ♂) — A world-leading kidney specialist at the University of Bristol, Saleem founded Purespring (launched with Syncona in 2020) to translate his podocyte research into AAV gene therapies delivered directly to the kidney.

Team & hubs

In the network

Shares the most investors with (number = shared investors):

Noema Pharma 3 Purespring Therapeutics 3 Mainstay Medical 2

Funding history

Date	Round	Amount
Oct 2024	Series B Purespring, a London gene-therapy biotech for kidney disease, raised a GBP80M Series B led by Sofinnova Partners.	$102M

Investors

Tap an investor to see what else they have backed.

Forbion Gilde Healthcare Sofinnova Partners Syncona Limited

Other companies in Biotech

Imperagen Haga Bioscience Pixelgen Technologies Gallant Chai Discovery SNIPR Biome Cellbox Labs Scope Biosciences GenLumina Actithera NUCLIDIUM Anocca

Other companies in GB

Capsa AI 01Health Rem3dy Health NewOrbit Joyvié Health Fuse Energy Airspeed Semble Wordsmith Oxford Quantum Circuits Fresha Imperagen

Other companies at Series B stage

0x Labs 11x.ai 1K Kirana 1X Technologies 1plusX 3Commas 3SC 4baseCare 4screen 8fig 9fin ACALL

Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.